好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Reversal of Vision Metamorphopsia and Hallucinations in a Cerebellar Peduncle Stroke: A Case Report
Cerebrovascular Disease and Interventional Neurology
P2 - Poster Session 2 (8:00 AM-9:00 AM)
13-020

To describe a cerebellar peduncle ischemic stroke associated with reversal of vision metamorphopsia and visual hallucinations.

Reversal of vision metamorphopsia (RVM) is a rare visual phenomenon described as an upside-down, 180-degree rotation of the visual field in the coronal plane. RVM has been reported in brainstem and cerebellar strokes, multiple sclerosis, migraines, seizures, and conditions that interrupt the peripheral vestibular system such as Meniere’s disease. Another rare form of visual perception dysfunction from a posterior circulation stroke is peduncular hallucinosis, which has been described as vivid, colorful visions of people and animals. RVM and visual hallucinosis are both thought to be transient conditions. The pathophysiology of RVM and peduncular hallucinosis remains unclear.

Case report

An 80-year-old man presented to the emergency department with acute onset dizziness, imbalance, reversal of vision metamorphopsia, and well-formed visual hallucinations of people, animals, and fire. MRI brain demonstrated an acute ischemic stroke in the inferior edge of the right cerebellar peduncle. EEG did not show any epileptiform activity. Visual hallucinations resolved by the time of discharge without any interventions, further supporting peduncular hallucinosis as the etiology. At follow-up, he denied further episodes of visual hallucinations, and RVM had improved significantly.

This case implies that the cerebellar peduncle is involved in integrating visual orientation and visual perception. Cerebellar strokes should be considered as a potential etiology in patients presenting with unexplained visual disturbances, particularly when accompanied by other neurological signs such as dizziness and ataxia. 
Authors/Disclosures
Fatemeh Sadeghifar, MD
PRESENTER
Dr. Sadeghifar has nothing to disclose.
Kostika Mulo, DO (UNC Health) Dr. Mulo has nothing to disclose.
Rebecca Traub, MD, FAAN (University of North Carolina Chapel Hill) Dr. Traub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Traub has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Traub has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Intellia. The institution of Dr. Traub has received research support from Alnylam Pharmaceuticals. The institution of Dr. Traub has received research support from Muscular Dystrophy Association (MDA). The institution of Dr. Traub has received research support from Ionis. The institution of Dr. Traub has received research support from Argenx. The institution of Dr. Traub has received research support from Pharnext. The institution of Dr. Traub has received research support from Immunovant. The institution of Dr. Traub has received research support from Takeda. Dr. Traub has received personal compensation in the range of $500-$4,999 for serving as a consultant with Department of Justice.
Michael Wang, MD Dr. Wang has nothing to disclose.